Clinical trial · Interventional
Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma
A Phase II Clinical Study of Endostar Combination With Chemotherapy in the Metastatic Nasopharyngeal Carcinoma
NCT01612286CI-TRIAL-00013786unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators designed this study to evaluate the efficiency and the acute toxicities of recombinant human endostatin (endostar) combined with chemotherapy in the metastatic nasopharyngeal carcinoma (NPC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| endostatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- endostatin
- description
- chemotherapy concurrently with endostatin
- interventionNames
- Drug: endostatin
Primary outcomes (1)
- measure
- progress free survival(PFS)
- timeFrame
- 1 year and 2years
- description
- PFS means assignament to the date of any local or distant progress of the disease useing Kaplan-Meier caculate the progress free survival rates
Secondary outcomes (2)
- measure
- overall survival(OS)
- timeFrame
- baseline to date of death from any cause
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosed metastatic NPC patient who have received radiotherapy or chemoradiotherapy with an at least 6 months interval * Have measurable lesions * No dysfunction of the major organs * Can understand this study and give a signed informed consent certificates * without a history of allergic reaction to the biological agents Exclusion Criteria: * Pregnant or lactating women; Women of child-bearing age without contraception * with a Serious infection or dysfunction of the major organs * have taken other antitumor drugs during the period of 30 days ahead of this clinical trial * allergic to the Escherichia coli preparations * Cann't understand this study and give a signed informed consent certificates
References
Publications (1)
- DERIVEDJin T, Li B, Chen XZ. A phase II trial of Endostar combined with gemcitabine and cisplatin chemotherapy in patients with metastatic nasopharyngeal carcinoma (NCT01612286). Oncol Res. 2013;21(6):317-23. doi: 10.3727/096504014X13983417587401. PMID 25198661